News Search Results
Active Filters
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
May 13, 2025, 16:49 ET Baricitinibe, da Lilly, proporcionou altas taxas de crescimento capilar em adolescentes com alopecia areata grave, aponta estudo
regrowth in adolescents with severe alopecia areata: 36-week efficacy and safety results from a Phase 3 randomized, controlled trial. American Academy of Dermatology Annual Meeting. March 7-11, 20252 Alopecia areata. National Alopecia Areata Foundation
More news about: Eli Lilly do Brasil